Califorrniaa v. lancu

CourtDistrict Court, E.D. Virginia
DecidedDecember 30, 2021
Docket1:20-cv-00985
StatusUnknown

This text of Califorrniaa v. lancu (Califorrniaa v. lancu) is published on Counsel Stack Legal Research, covering District Court, E.D. Virginia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Califorrniaa v. lancu, (E.D. Va. 2021).

Opinion

UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF VIRGINIA Alexandria Division

EURICA CALIFORNIAA,

Plaintiff, Civil No. 1-20-cv-00985-MSN-TCB v.

ANDREW HIRSHFELD,1 Performing the Duties of Under Secretary of Commerce for Intellectual Property and Deputy Director of the United States Patent and Trademark Office, Defendant.

MEMORANDUM OPINION This matter comes before the Court on plaintiff Eurica Californiaa’s Motion for Summary Judgment (Dkt. No. 11) and defendant Andrew Hirshfeld’s Cross Motion for Summary Judgment (Dkt. No. 13). This action arises from plaintiff’s challenge to the United States Patent and Trademark Office’s (“USPTO”) patent term adjustment (“PTA”) determination for United States Patent No. 10,245,075 (the “‘075 patent”). The parties’ competing positions on the merits of the USPTO’s PTA determination have been fully briefed, making their motions ripe for disposition. For the reasons that follow, the Court will DENY plaintiff’s motion and GRANT defendant’s cross motion.

1 Andrew Hirschfeld is performing the functions and duties of the Under Secretary of Commerce for the Intellectual Property and Deputy Director of the United States Patent and Trademark Office and is automatically substituted as a party pursuant to Fed. R. Civ. P. 25(d). BACKGROUND When an applicant files a patent application with the USPTO, a USPTO patent examiner reviews the application—a process known as “examination”—to determine whether to issue a patent. See 35 U.S.C. § 131. Examiner and applicant go through a series of back and forth edits

until the examiner determines the claims should be rejected or accepted. Pfizer, Inc. v. Lee, 811 F.3d 466, 475–76 (Fed. Cir. 2016). If the examiner determines a patent is warranted, the examiner issues a “Notice of Allowability” that sets out the terms of the patent that will subsequently be issued. Def. Mem. (Dkt. No. 14) at 5 (citing Manual of Patent Examining Procedure at ¶ 1302.03). The USPTO also provides the applicant with a more formal “Notice of Allowance” that identifies additional fees owed before a patent can issue. Id. (citing Manual of Patent Examining Procedure at ¶ 1303). At this point, examination and prosecution of the patent are complete, unless the examination is reopened on the merits. See Novartis AG v. Lee, 740 F. 3d 593, 602 (Fed. Cir. 2014). If an applicant is dissatisfied with the patent claims laid out in the Notice of Allowance, the applicant may file a request to amend the claims under 37 C.F.R. § 1.312. See Def. Mem. at 5–6.

This “after allowance” amendment effectively reopens the patent examination process. In simplified terms, once the amendment is addressed and there are no additional changes to the patent application, the patent is issued. A patent term, i.e. the length of time the patent is enforceable, is calculated starting from the day the application is submitted to the USPTO. When determining the patent term, the USPTO accounts for delays caused by either the examiner or applicant that may have occurred during examination. For example, there are three types of statutorily-required adjustments to the patent term when the USPTO fails to meet benchmarks in the examination process or an applicant successfully challenges a negative patent eligibility determination. See generally 35 U.S.C. § 154(b)(1).2 The USPTO is also statutorily required to account for delays in the patent examination “during which the applicant failed to engage in reasonable efforts to conclude [prosecution, processing, or examination] of the application.” 35 U.S.C. § 154(b)(2)(C). The PTA is the sum of the delays caused by the USPTO and the applicant. See Intra-

Cellular Therapies, Inc. v. Iancu, 938 F.3d 1371, 1374 (Fed. Cir. 2019) (discussing PTA adjustments). The patent term is increased if delays were due to the USPTO or decreased if due to the applicant. If an applicant is dissatisfied with the PTA determination, the applicant may file a request for reconsideration. See 35 U.S.C. § 154(b)(3)(B)(ii). If the applicant is still dissatisfied with the PTA determination after reconsideration, the applicant may seek Article III review in this Court. See id. § 154(b)(4)(A). PROCEDURAL HISTORY Plaintiff owns the ‘075 patent issued on April 2, 2019. In calculating the PTA for ‘075, the USPTO released an Issue Notification on March 13, 2019, which included a PTA of 1,018 days. Admin. Record (Dkt. No. 7-3) at 130. That PTA calculation was based in part on a finding that the

applicant was responsible for 51 days of delay during the patent’s prosecution under 37 C.F.R. § 1.704(c)(10). The USPTO tied these 51 days of delay to an amendment plaintiff filed pursuant to 37 C.F.R. § 1.312 after he received the ‘075 patent’s Notice of Allowance. Id. at 142. Plaintiff filed a request for reconsideration on April 3, 2019, asking that the USPTO recalculate the ‘075 patent’s PTA at 1,069 days. Id. at 139. In support, plaintiff argued that he was required to file the Section 1.312 amendment in response to an “Examiner’s Amendment” that

2 An “A delay” occurs when the examiner fails to send a Notice of Allowance within fourteen (14) months after an application is filed. See 35 U.S.C. § 154(b)(1)(A)(i)(I). A “B delay” occurs when the USPTO fails to issue a patent within “three years after the actual filing of the application in the United States.” Id. § 154(b)(1)(B). Lastly, a “C delay” is caused when the patent applicant is successful in challenging an administrative or judicial decision. See id. § 154(b)(1)(C). Any days that overlap between an A, B, and C delay are deducted from the PTA determination. See id. § 154(b)(2)(A). appeared for the first time in the ‘075 patent’s Notice of Allowance. Id. at 142. Plaintiff further asserted that because he had no other way to address that “Examiner’s Amendment,” he should not be penalized for filing a responsive Section 1.312 amendment. Id. The USPTO disagreed and denied plaintiff’s request on March 30, 2020. See id. at 138–145. This action followed pursuant to

35 U.S.C. § 154(b)(4). See id. at 139; Compl. (Dkt. No. 1) at ¶¶ 17–19. LEGAL STANDARD Summary judgment is proper where, viewing the facts in a light most favorable to the non- moving party, there remains no genuine issue of material fact and the evidence demonstrates the moving party is entitled to judgment as a matter of law. Fed. R. Civ. P. 56(c); Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 247-48 (1986); Evans v. Techs. Applications & Serv.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
United States v. Mead Corp.
533 U.S. 218 (Supreme Court, 2001)
Buckingham v. Mabus
772 F. Supp. 2d 295 (District of Columbia, 2011)
R.R. Donnelley & Sons Co. v. Dickinson
123 F. Supp. 2d 456 (N.D. Illinois, 2000)
Novartis Ag v. Focarino
740 F.3d 593 (Federal Circuit, 2014)
Gilead Sciences, Inc. v. Lee
778 F.3d 1341 (Federal Circuit, 2015)
Pfizer, Inc. v. Lee
811 F.3d 466 (Federal Circuit, 2016)
Intra-Cellular Therapies, Inc v. Iancu
938 F.3d 1371 (Federal Circuit, 2019)
Rocky Mountain Health Maint. Org., Inc. v. Price
297 F. Supp. 3d 152 (D.C. Circuit, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Califorrniaa v. lancu, Counsel Stack Legal Research, https://law.counselstack.com/opinion/califorrniaa-v-lancu-vaed-2021.